<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Thirty-one patients, 13 adults and 18 children, were included in a phase II study of combined treatment with CDDP 40 mg/m2 and <z:chebi fb="0" ids="4911">VP16</z:chebi> 100 or 200 mg/m2 for 5 days </plain></SENT>
<SENT sid="1" pm="."><plain>Fourteen patients were primary refractory to front-line treatment and 17 were treated at relapse (9 on therapy, 8 off therapy) </plain></SENT>
<SENT sid="2" pm="."><plain>Four were low-grade follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, 7 intermediate grade <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, and 20 high grade <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>One of the 14 primary refractory cases responded (CR) whereas 3 PR and 10 CR were observed among the 17 relapses </plain></SENT>
<SENT sid="4" pm="."><plain>Toxicity was acceptable </plain></SENT>
<SENT sid="5" pm="."><plain>9 patients are still alive after bone marrow transplantation (median survival, 16 months) </plain></SENT>
<SENT sid="6" pm="."><plain>This combination is an effective salvage regime before autologous bone marrow transplantation for relapsed NHL, but cannot be recommended for progression on front-line therapy </plain></SENT>
</text></document>